Fort Wayne Medical Oncology and Hematology (Fort Wayne North)
Fort Wayne North Office
Fort Wayne, IN
Accepting patients
ON-TRK
PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib
- Tyrosine Kinase (TK) Inhibitor
Not yet accepting
TRIDENT-1
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
- Tyrosine Kinase (TK) Inhibitor
- Phase 1/2
- Has results